The pandemic ensured that 2020 was unlike any other year for biopharma and medtech companies. But, while these sectors turned their collective attentions to vanquishing the novel coronavirus, the usual business of drug and device development continued alongside. This report is a round-up of Evaluate Vantage’s analyses of 2020 – from M&A, venture financing and IPO markets, In many ways Covid-19 turbocharged an industry that was already riding fairly high. The financing climate had been strong for a few years, but 2020 saw records broken in the venture and IPO worlds. With the spotlight on biopharma, which made remarkably swift progress on a pipeline of pandemic therapies, investors rushed to inject money into the sector.